119 related articles for article (PubMed ID: 29989222)
1. Evaluation of oral pharmacokinetics, in vitro metabolism, blood partitioning and plasma protein binding of novel antidiabetic agent, S009-0629 in rats.
Valicherla GR; Italiya KS; Gupta CP; Mishra S; Riyazuddin M; Syed AA; Singh SK; Shahi S; Taneja G; Wahajuddin M; Goel A; Gayen JR
Drug Dev Res; 2018 Jun; 79(4):173-183. PubMed ID: 29989222
[TBL] [Abstract][Full Text] [Related]
2. Assessment of in vitro metabolic stability, plasma protein binding, and pharmacokinetics of E- and Z-guggulsterone in rat.
Chhonker YS; Chandasana H; Mukkavilli R; Prasad YD; Laxman TS; Vangala S; Bhatta RS
Drug Test Anal; 2016 Sep; 8(9):966-75. PubMed ID: 26608935
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic characterization of 2-(3-benzoyl)-4-hydroxy-1,1-dioxo-2H-1,2-benzothiazine-2-yl-1-phenylethanone, a novel 11β-hydroxysteroid dehydrogenase type 1 inhibitor in rats.
Zheng Z; Seo H; Kwak HJ; Kim KY; Ahn JH; Bae MA; Song JS
Arch Pharm Res; 2016 Apr; 39(4):492-498. PubMed ID: 26780247
[TBL] [Abstract][Full Text] [Related]
4. In-situ absorption, protein binding and pharmacokinetic studies of S002-853, a novel antidiabetic and antidyslipidaemic flavone derivative in rats.
Gautam N; Kushwaha HN; Pratap R; Singh SK
J Pharm Pharmacol; 2010 May; 62(5):604-9. PubMed ID: 20609062
[TBL] [Abstract][Full Text] [Related]
5. Preclinical pharmacokinetics and ADME characterization of a novel anticancer chalcone, cardamonin.
Jaiswal S; Shukla M; Sharma A; Rangaraj N; Vaghasiya K; Malik MY; Lal J
Drug Test Anal; 2017 Aug; 9(8):1124-1136. PubMed ID: 27794181
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics, plasma protein binding, and metabolism of a potential natural chemosensitizer from Marsdenia tenacissima in rats.
Xie B; Jiang SQ; Shen XL; Wu HQ; Hu YJ
J Ethnopharmacol; 2021 Dec; 281():114544. PubMed ID: 34419608
[TBL] [Abstract][Full Text] [Related]
7. Acute liver failure enhances oral plasma exposure of zidovudine in rats by downregulation of hepatic UGT2B7 and intestinal P-gp.
Wang F; Miao MX; Sun BB; Wang ZJ; Tang XG; Chen Y; Zhao KJ; Liu XD; Liu L
Acta Pharmacol Sin; 2017 Nov; 38(11):1554-1565. PubMed ID: 28770824
[TBL] [Abstract][Full Text] [Related]
8. Determination of geniposide in adjuvant arthritis rat plasma by ultra-high performance liquid chromatography tandem mass spectrometry method and its application to oral bioavailability and plasma protein binding ability studies.
Chen J; Wu H; Xu GB; Dai MM; Hu SL; Sun LL; Wang W; Wang R; Li SP; Li GQ
J Pharm Biomed Anal; 2015 Apr; 108():122-8. PubMed ID: 25771205
[TBL] [Abstract][Full Text] [Related]
9. Preclinical absorption, distribution, metabolism, excretion and pharmacokinetics of a novel selective inhibitor of breast cancer resistance protein (BCRP).
Liao M; Chuang BC; Zhu Q; Li Y; Guan E; Yu S; Yang J; Prakash S; Xia CQ
Xenobiotica; 2018 May; 48(5):467-477. PubMed ID: 28485193
[TBL] [Abstract][Full Text] [Related]
10. Elucidation of pharmacokinetics of novel DNA ligase I inhibitor, S012-1332 in rats: Integration of in vitro and in vivo findings.
Riyazuddin M; Valicherla GR; Husain A; Hussain MK; Shukla M; Katekar R; Gupta AP; Singh P; Banerjee D; Hajela K; Gayen JR
J Pharm Biomed Anal; 2019 Jan; 162():205-214. PubMed ID: 30265980
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the Pharmacokinetics of the Pancreastatin Inhibitor PSTi8 Peptide in Rats: Integration of In Vitro and In Vivo Findings.
Valicherla GR; Katekar RA; Dadge S; Riyazuddin M; Syed AA; Singh SK; Husain A; Wahajuddin M; Gayen JR
Molecules; 2022 Jan; 27(2):. PubMed ID: 35056659
[TBL] [Abstract][Full Text] [Related]
12. Influence of cholestyramine on the pharmacokinetics of rosiglitazone and its metabolite, desmethylrosiglitazone, after oral and intravenous dosing of rosiglitazone: impact on oral bioavailability, absorption, and metabolic disposition in rats.
Muzeeb S; Venkatesh P; Mullangi R; Srinivas NR
Xenobiotica; 2006 Sep; 36(9):838-56. PubMed ID: 16971347
[TBL] [Abstract][Full Text] [Related]
13. Bioanalytical LC-MS/MS method development and validation of novel antidiabetic candidate S007-1261 in rat plasma and its application to pharmacokinetic and oral bioavailability studies.
Misra A; Kushwaha HN; Gautam N; Singh B; Verma PC; Pratap R; Singh SK
Drug Res (Stuttg); 2014 Aug; 64(8):399-405. PubMed ID: 24258707
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous determination of imperatorin and its metabolites in vitro and in vivo by a GC-MS method: application to a bioavailability and protein binding ability study in rat plasma.
Zhao G; Peng C; Du W; Wang S
Biomed Chromatogr; 2014 Jul; 28(7):947-56. PubMed ID: 24357077
[TBL] [Abstract][Full Text] [Related]
15. Preclinical comprehensive physicochemical and pharmacokinetic profiling of novel nitroimidazole derivative IIIM-019 - A potential oral treatment for tuberculosis.
Kour G; Kumar A; Singh PP; Sharma S; Bhagat A; Vishwakarma RA; Ahmed Z
Pulm Pharmacol Ther; 2016 Oct; 40():44-51. PubMed ID: 27457685
[TBL] [Abstract][Full Text] [Related]
16. P-glycoprotein (MDR1/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) restrict brain accumulation of the JAK1/2 inhibitor, CYT387.
Durmus S; Xu N; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
Pharmacol Res; 2013 Oct; 76():9-16. PubMed ID: 23827160
[TBL] [Abstract][Full Text] [Related]
17. Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar.
Tang SC; Nguyen LN; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
Int J Cancer; 2014 Mar; 134(6):1484-94. PubMed ID: 24037730
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic evaluation of medicinally important synthetic N,N' diindolylmethane glucoside: Improved synthesis and metabolic stability.
Magotra A; Gour A; Sharma DK; Dash AK; Singh G; Mukherjee D; Nandi U
Bioorg Med Chem Lett; 2019 Apr; 29(8):1007-1011. PubMed ID: 30777609
[TBL] [Abstract][Full Text] [Related]
19. Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL.
Kamath AV; Wang J; Lee FY; Marathe PH
Cancer Chemother Pharmacol; 2008 Mar; 61(3):365-76. PubMed ID: 17429625
[TBL] [Abstract][Full Text] [Related]
20. Dose-linear pharmacokinetics of oleanolic acid after intravenous and oral administration in rats.
Jeong DW; Kim YH; Kim HH; Ji HY; Yoo SD; Choi WR; Lee SM; Han CK; Lee HS
Biopharm Drug Dispos; 2007 Mar; 28(2):51-7. PubMed ID: 17163409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
